(NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI ® (encorafenib) in ...

Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...

May 29 (Reuters) - China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and ...

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer China's ...

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions ...

Pfizer and Innovent Biologics signed a licensing agreement to research and develop 12 cancer medicines. The agreement includes licensing, co-development and co-commercialization across the ...

A cancer diagnosis changes how people measure time. This article explores how advances in oncology research, precision ...

Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and ...

Pfizer Inc. and China’s Innovent Biologics Inc. signed a global agreement worth as much as $10.5 billion to develop cancer drugs, highlighting surging demand for Chinese drugs despite the geopolitical ...

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.